Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Eribulin (HALAVEN) Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry

NCT02443428 is registered in ClinicalTrials.gov with Eisai Limited as lead sponsor.

NCT NCT02443428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02443428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Eribulin (HALAVEN) Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry
Lead sponsor
Eisai Limited
Phase
Observational
Overall status
Completed
Start date
August 31, 2013
Completion date
October 31, 2015
Enrollment
77 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer